Kyotorphin

Kyotorphin (Tyr-Arg) is an endogenous analgesic dipeptide isolated from bovine brain in 1979. It is one of the simplest known neuroactive peptides — just two amino acids — yet produces potent naloxone-reversible analgesia when administered centrally. Kyotorphin is concentrated in synaptosomes of pain-relevant brain regions and is synthesized by a dedicated kyotorphin synthase from tyrosine and arginine. It binds a distinct G protein-coupled receptor and may act as an endogenous opioid modulator rather than a direct opioid receptor agonist.

Kyotorphin does not directly bind classical mu, delta, or kappa opioid receptors with high affinity. Its analgesic effect appears to be mediated indirectly: kyotorphin stimulates the release of met-enkephalin from nerve terminals, which then acts on delta and mu opioid receptors to produce analgesia. A specific kyotorphin receptor (KTP-R) coupled to a Gi-type G protein has been proposed but is not yet definitively identified. Kyotorphin is unevenly distributed in the brain, concentrated in the midbrain, pons/medulla, and dorsal spinal cord — regions with the highest sensitivity to morphine analgesia — consistent with a physiological role in pain modulation.

Kyotorphin research peaked in the 1980s–1990s and has seen renewed interest with the identification of its receptor and potential for antimicrobial applications. Central administration produces dose-dependent analgesia blocked by naloxone, confirming opioid-pathway involvement. Brain regional distribution studies place it in major pain processing nodes. More recent research has explored kyotorphin analogs with improved blood-brain barrier penetration and resistance to peptidase cleavage. Antimicrobial properties against bacterial membranes have also been reported. No therapeutic agents derived from kyotorphin have advanced to clinical trials.